Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

References

• NagarajSGuptaKPisarevVAltered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancerNature Med200713782883517603493
   PubMed Web of Science ®Google Scholar
• HiramotoKSatohHSuzukiTMyeloid lineage–specific deletion of antioxidant system enhances tumor metastasisCancer Prev Res201478835844
   PubMedGoogle Scholar
• SawantASchaferCCJinTHEnhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathwaysCancer Res201373226609662024085788
   PubMed Web of Science ®Google Scholar
• NagarajSYounJIWeberHAnti-inflammatory triterpenoid blocks immune suppressive function of myeloid-derived suppressor cells and improves immune response in cancerClin Cancer Res20101661812182320215551
   PubMed Web of Science ®Google Scholar
• HuertaCJiangXTrevinoICharacterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 bindingBiochim Biophys Acta2016186011 Pt A2537255227474998
   PubMedGoogle Scholar
• CleasbyAYonJDayPJStructure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDOPLoS One201496e9889624896564
   PubMed Web of Science ®Google Scholar
• StewartJHengstlerJBoltHControl of oxidative stress by the Keap1-Nrf2 pathwayArch Toxicol201185423921431330
   PubMed Web of Science ®Google Scholar
• ProbstBLTrevinoIMcCauleyLRTA 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activityPLoS One2015104e012294225897966
   PubMed Web of Science ®Google Scholar
• AlexeevVLashEAguillardARadiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compoundMol Cancer Ther201413122968297725398830
   PubMedGoogle Scholar
• GoldmanDCAlexeevVLashEGuhaCRodeckUFlemingWHThe triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in miceRadiat Res2015183333834425738896
   PubMedGoogle Scholar
• ReismanSALeeC-YIMeyerCJProkschJWSonisSTWardKWTopical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitisRadiat Res2014181551252024720753
   PubMedGoogle Scholar
• ReismanSALeeCYMeyerCJProkschJWWardKWTopical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skinArch Dermatol Res2014306544745424362512
   PubMed Web of Science ®Google Scholar
• ReismanSAGoldsberryARLeeCYTopical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteersBMC Dermatol20151511026170027
   PubMedGoogle Scholar
• LiuXWardKXavierCThe novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H 2 O 2-induced cell injury via NF-E2-related factor 2 (Nrf2) activationRedox Biol201689810926773873
   PubMed Web of Science ®Google Scholar
• EisenhauerETherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• ChinMPReismanSABakrisGLMechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methylAm J Nephrol201439649950824903467
   PubMed Web of Science ®Google Scholar
• Reata Pharmaceuticals, IncRTA 408 Capsules in patients with melanoma – REVEAL2017 Available from: https://clinicaltrials.gov/ct2/show/NCT02259231. NLM identifier NCT02259231Accessed March 6, 2017
   Google Scholar
• Reata Pharmaceuticals, IncRTA 408 Capsules in patients with mitochondrial myopathy – MOTOR2017 Available from: https://clinicaltrials.gov/ct2/show/NCT02255422. NLM identifier NCT02255422Accessed March 6, 2017
   Google Scholar
• Reata Pharmaceuticals, IncRTA 408 Capsules in patients with Friedreich’s ataxia – MOXIe NLM identifier. NCT02255435. Available from: https://clinicaltrials.gov/ct2/show/NCT02255435Accessed March 6, 2017
   Google Scholar
• TayekJAKalantar-ZadehKThe extinguished BEACON of bardoxolone: not a Monday morning quarterback storyAm J Nephrol201337320821123466901
   PubMed Web of Science ®Google Scholar
• OudizRJMeyerCJMelanieCInitial Data Report from “LARIAT”: A Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background TherapyChest20151484: Meeting Abstracts639A
   Google Scholar
• HongDSKurzrockRSupkoJGA phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasClin Cancer Res201218123396340622634319
   PubMed Web of Science ®Google Scholar
• SperanzaGGutierrezMEKummarSPhase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumorsCancer Chemother Pharmacol201269243143821805353
   PubMedGoogle Scholar
• TsaoTKornblauSSafeSRole of peroxisome proliferator-activated receptor-γ and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemiaCancer Res201070124949496020501850
   PubMed Web of Science ®Google Scholar
• HossainFAl-KhamiAAWyczechowskaDInhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapiesCancer Immunol Res20153111236124726025381
   PubMed Web of Science ®Google Scholar
• ShenLSundstedtACiesielskiMTasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsCancer Immunol Res20153213614825370534
   PubMed Web of Science ®Google Scholar
• CallahanMKHorakCECurranMAPeripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumabJournal of Clinical Oncology201331153003
   Google Scholar
• WeberJGibneyGKudchadkarRPhase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumabCancer Immunol Res20164434535326873574
   PubMed Web of Science ®Google Scholar
• GebhardtCSevkoAJiangHMyeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumabClin Cancer Ress2015212454535459
   PubMed Web of Science ®Google Scholar
• JayaramanPParikhFKruparRPariharRVarierISikoraAAbstract PR005: TGF-beta1 primed myeloid derived suppressor cells decrease tumor growth and lose their ability to inhibit T cell proliferation via iNOS downregulationCancer Immunol Res20164Suppl 1PR005PR005
   Google Scholar
• MaoYEisslerNLe BlancKJohnsenJIKognerPKiesslingRTargeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastomaClin Cancer Res201622153849385926957560
   PubMed Web of Science ®Google Scholar
• VelaMArisMLlorenteMGarcia-SanzJAKremerLChemokine receptor-specific antibodies in cancer immunotherapy: achievements and challengesFronts Immunol2015612
   PubMedGoogle Scholar
• BeattyGLChioreanEGFishmanMPCD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansScience201133160241612161621436454
   PubMed Web of Science ®Google Scholar
• DahanRBarnhartBCLiFYamniukAPKormanAJRavetchJVTherapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagementCancer Cell201629682083127265505
   PubMed Web of Science ®Google Scholar
• IbbersonMBronSGuexNTIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2–expressing monocytes in human breast tumorsClin Cancer Res201319133439344923649001
   PubMedGoogle Scholar
• PankaDJArbeitRDMierJWRegulation of MDSC trafficking and function in RCC by CXCR4 in the presence of a VEGF-R antagonistAACR20167614 Abstract 4155
   Google Scholar
• Dinkova-KostovaATBairdLHolmströmKMMeyerCJAbramovAYThe spatiotemporal regulation of the Keap1–Nrf2 pathway and its importance in cellular bioenergeticsBiochem Soc Trans201543460261026551700
   PubMedGoogle Scholar
• LibyKTSpornMBSynthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic diseasePharmacol Rev2012644972100322966038
   PubMed Web of Science ®Google Scholar